The ENDECE team is supplemented by our Scientific Advisory Board, comprised of exceptional external resources.

Doug Arnold, M.D.

Clinical Advisor


Douglas Arnold, MD is a Professor in the Department of Neurology and Neurosurgery at McGill University, Director of the Magnetic Resonance Spectroscopy Unit in the Brain Imaging Center at the Montreal Neurological Institute, and President of NeuroRx Research, a CNS imaging CRO. He has special expertise in advanced MRI acquisition and analysis techniques, particularly as they relate to understanding the evolution of multiple sclerosis and the measurement of markers of inflammation, remyelination and neuroprotection.

Andrew Liebermann, M.D., Ph.D.

Clinical Advisor

Niemann-Pick disease type C

Jeffrey Cohen, M.D.

Clinical Advisor

Multiple Sclerosis

Director of the Experimental Therapeutics Program and the Clinical Neuroimmunology Fellowship at the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic.

In addition to his large clinical practice devoted primarily to the care of patients with multiple sclerosis (MS) and related disorders, Dr. Cohen has been involved in a large number of clinical trials investigating potential new therapies for MS. A world-renowned expert on MS, Dr. Cohen has served on a large number of grant review committees, advisory groups, and national and international task forces.

Bruce Trapp, Ph.D.

Scientific Advisor


Professor and Chairman, Department of Neurosciences, Cleveland Clinic Foundation. Recipient of awards including the Harry Weaver Neuroscience Scholar Award from the National Multiple Sclerosis Society (NMSS) and the John Dystel Prize for MS Research from the American Academy of Neurology and the NMSS.

Michael Levy, M.D., Ph.D.

Clinical Advisor

Neuromyelitis Optica Spectrum Disorder

Dr. Michael Levy, MD, PhD, is an Assistant Professor of Neurology at the Johns Hopkins University and Director of the Neuromyelitis Optica Clinic.

Dr. Levy specializes in caring for patients with rare neuroimmunologic diseases including neuromyelitis optica, transverse myelitis and recurrent optic neuritis. In addition to four monthly clinics, Dr. Levy is the Principal Investigator on several clinical studies and drug trials for these conditions.

Upon completing the MD/PhD program at Baylor College of Medicine (Houston, TX) with a focus on neuroscience, Dr. Levy came to Johns Hopkins in 2004 for a 1-year internship in the Osler Medicine program followed by a 3 year residency in the Hopkins neurology program and a 2 year fellowship in Neuroimmunology. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor.

Benjamin Greenberg, M.D., M.H.S.

Clinical Advisor

Neuromyelitis Optica Spectrum Disorder

Benjamin M. Greenberg, M.D., M.H.S., is an Associate Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology and Neurotherapeutics and the Department of Pediatrics at UT Southwestern Medical Center. 

He serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program, and the Pediatric Demyelinating Disease Program at Children’s Medical Center and is currently the Vice Chair of Translational Research for the Department of Neurology and Directs the Neurosciences Translational Research Center at UT Southwestern.

Dr. Greenberg is an internationally recognized expert in treating rare autoimmune disorders of the central nervous system. He is the principal investigator for the first large scale study of pediatric TM, coordinator centers throughout North America in a collaborative effort to better understand this rare disease.

His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections.

In addition to coordinating clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients., Dr. Greenberg has led an effort to improve biorepository development and create uniform protocols for sample handling and analysis. As part of this initiative, his collaborative research has identified novel biomarkers that may be key to distinguishing between patients with various neurologic disorders.